1. participant is pregnant or planning to become pregnant within 3 months after study vaccine administration. 2. history of allergy to any component of the vaccine. 3. significant infection (e.g. positive sars-cov-2 rt-pcr) or other acute illness, including fever \> 100 °f (\> 37.8 °c) 48 hours before vaccination. 4. participant has a known or suspected defect of the immune system 5. participant has a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome. 6. participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. if there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the participant may be enrolled. a history of hematologic malignancy is a permanent exclusion. participants with a history of skin cancer must not be vaccinated at the previous tumour site. 7. history of drug dependency or current use of drug of abuse or alcohol abuse at screening. 8. significant blood loss (\> 450 ml) or has donated 1 or more units of blood or plasma within 6 weeks prior to the expected day of randomization (visit 1). 9. history of clinically significant bleeding disorder, or prior history of significant bleeding or bruising following im injections or venepuncture. 10. severe and uncontrolled ongoing autoimmune or inflammatory disease history of guillain-barre syndrome or any other demyelinating condition. 11. any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the volunteer prior/concomitant therapy: 12. receipt of immunoglobulin or another blood product within the 3 months before expected day of randomization (visit 1) in this study or those who expect to receive immunoglobulin or another blood product during this study. 13. receipt of medications and or vaccinations intended to prevent covid-19. 14. receipt of any vaccine (licensed or investigational), other than licensed influenza vaccine, within 28 days prior to the expected day of randomization (visit 1). 15. any member of the study team or sponsor. 16. an immediate family member or household member of the study's personnel. booster vaccination (adults and adolescents) in addition to the above-described eligibility criteria, the following criteria must be met: 1. participant has not received another licensed covid-19 vaccine during the study

1. participant is pregnant or planning to become pregnant within 3 months after study vaccine administration. 2. history of allergy to any component of the vaccine. 3. significant infection (e.g. positive sars-cov-2 rt-pcr) or other acute illness, including fever \> 100 °f (\> 37.8 °c) 48 hours before vaccination. 4. participant has a known or suspected defect of the immune system 5. participant has a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome. 6. participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. if there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the participant may be enrolled. a history of hematologic malignancy is a permanent exclusion. participants with a history of skin cancer must not be vaccinated at the previous tumour site. 7. history of drug dependency or current use of drug of abuse or alcohol abuse at screening. 8. significant blood loss (\> 450 ml) or has donated 1 or more units of blood or plasma within 6 weeks prior to the expected day of randomization (visit 1). 9. history of clinically significant bleeding disorder, or prior history of significant bleeding or bruising following im injections or venepuncture. 10. severe and uncontrolled ongoing autoimmune or inflammatory disease history of guillain-barre syndrome or any other demyelinating condition. 11. any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the volunteer prior/concomitant therapy: 12. receipt of immunoglobulin or another blood product within the 3 months before expected day of randomization (visit 1) in this study or those who expect to receive immunoglobulin or another blood product during this study. 13. receipt of medications and or vaccinations intended to prevent covid-19. 14. receipt of any vaccine (licensed or investigational), other than licensed influenza vaccine, within 28 days prior to the expected day of randomization (visit 1). 15. any member of the study team or sponsor. 16. an immediate family member or household member of the study's personnel. booster vaccination (adults and adolescents) in addition to the above-described eligibility criteria, the following criteria must be met: 1. participant has not received another licensed covid-19 vaccine during the study

participant is pregnant or planning to become pregnant within 3 months after study vaccine administration. history of allergy to any component of the vaccine. significant infection (e.g. positive sars-cov-2 rt-pcr) or other acute illness, including fever > 100 °f (> 37.8 °c) 48 hours before vaccination. participant has a known or suspected defect of the immune system participant has a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome. participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. if there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the participant may be enrolled. a history of hematologic malignancy is a permanent exclusion. participants with a history of skin cancer must not be vaccinated at the previous tumour site. history of drug dependency or current use of drug of abuse or alcohol abuse at screening. significant blood loss (> 450 ml) or has donated 1 or more units of blood or plasma within 6 weeks prior to the expected day of randomization (visit 1). history of clinically significant bleeding disorder, or prior history of significant bleeding or bruising following im injections or venepuncture. severe and uncontrolled ongoing autoimmune or inflammatory disease history of guillain-barre syndrome or any other demyelinating condition. any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the volunteer prior/concomitant therapy: receipt of immunoglobulin or another blood product within the 3 months before expected day of randomization (visit 1) in this study or those who expect to receive immunoglobulin or another blood product during this study. receipt of medications and or vaccinations intended to prevent covid-19. receipt of any vaccine (licensed or investigational), other than licensed influenza vaccine, within 28 days prior to the expected day of randomization (visit 1). any member of the study team or sponsor. an immediate family member or household member of the study's personnel. booster vaccination (adults and adolescents) in addition to the above-described eligibility criteria, the following criteria must be met: 1. participant has not received another licensed covid-19 vaccine during the study

participant is pregnant or planning to become pregnant within 3 months after study vaccine administration. history of allergy to any component of the vaccine. significant infection (e.g. positive sars-cov-2 rt-pcr) or other acute illness, including fever > 100 °f (> 37.8 °c) 48 hours before vaccination. participant has a known or suspected defect of the immune system participant has a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome. participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. if there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the participant may be enrolled. a history of hematologic malignancy is a permanent exclusion. participants with a history of skin cancer must not be vaccinated at the previous tumour site. history of drug dependency or current use of drug of abuse or alcohol abuse at screening. significant blood loss (> 450 ml) or has donated 1 or more units of blood or plasma within 6 weeks prior to the expected day of randomization (visit 1). history of clinically significant bleeding disorder, or prior history of significant bleeding or bruising following im injections or venepuncture. severe and uncontrolled ongoing autoimmune or inflammatory disease history of guillain-barre syndrome or any other demyelinating condition. any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the volunteer prior/concomitant therapy: receipt of immunoglobulin or another blood product within the 3 months before expected day of randomization (visit 1) in this study or those who expect to receive immunoglobulin or another blood product during this study. receipt of medications and or vaccinations intended to prevent covid-19. receipt of any vaccine (licensed or investigational), other than licensed influenza vaccine, within 28 days prior to the expected day of randomization (visit 1). any member of the study team or sponsor. an immediate family member or household member of the study's personnel. booster vaccination (adults and adolescents) in addition to the above-described eligibility criteria, the following criteria must be met: 1. participant has not received another licensed covid-19 vaccine during the study

participant is pregnant or planning to become pregnant within 3 months after study vaccine administration. history of allergy to any component of the vaccine. significant infection (e.g. positive sars-cov-2 rt-pcr) or other acute illness, including fever > 100 °f (> 37.8 °c) 48 hours before vaccination. participant has a known or suspected defect of the immune system participant has a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome. participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. if there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the participant may be enrolled. a history of hematologic malignancy is a permanent exclusion. participants with a history of skin cancer must not be vaccinated at the previous tumour site. history of drug dependency or current use of drug of abuse or alcohol abuse at screening. significant blood loss (> 450 ml) or has donated 1 or more units of blood or plasma within 6 weeks prior to the expected day of randomization (visit 1). history of clinically significant bleeding disorder, or prior history of significant bleeding or bruising following im injections or venepuncture. severe and uncontrolled ongoing autoimmune or inflammatory disease history of guillain-barre syndrome or any other demyelinating condition. any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the volunteer prior/concomitant therapy: receipt of immunoglobulin or another blood product within the 3 months before expected day of randomization (visit 1) in this study or those who expect to receive immunoglobulin or another blood product during this study. receipt of medications and or vaccinations intended to prevent covid-19. receipt of any vaccine (licensed or investigational), other than licensed influenza vaccine, within 28 days prior to the expected day of randomization (visit 1). any member of the study team or sponsor. an immediate family member or household member of the study's personnel. booster vaccination (adolescents) in addition to the above described eligibility criteria, the following criteria must be met: - participant has completed the primary vaccination schedule per protocol (i.e. has received 2 study vaccinations within protocol windows).

participant is pregnant or planning to become pregnant within 3 months after study vaccine administration. history of allergy to any component of the vaccine. significant infection (e.g. positive sars-cov-2 rt-pcr) or other acute illness, including fever > 100 °f (> 37.8 °c) 48 hours before vaccination. participant has a known or suspected defect of the immune system participant has a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome. participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. if there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the participant may be enrolled. a history of hematologic malignancy is a permanent exclusion. participants with a history of skin cancer must not be vaccinated at the previous tumour site. history of drug dependency or current use of drug of abuse or alcohol abuse at screening. significant blood loss (> 450 ml) or has donated 1 or more units of blood or plasma within 6 weeks prior to the expected day of randomization (visit 1). history of clinically significant bleeding disorder, or prior history of significant bleeding or bruising following im injections or venepuncture. severe and uncontrolled ongoing autoimmune or inflammatory disease history of guillain-barre syndrome or any other demyelinating condition. any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the volunteer prior/concomitant therapy: receipt of immunoglobulin or another blood product within the 3 months before expected day of randomization (visit 1) in this study or those who expect to receive immunoglobulin or another blood product during this study. receipt of medications and or vaccinations intended to prevent covid-19. receipt of any vaccine (licensed or investigational), other than licensed influenza vaccine, within 28 days prior to the expected day of randomization (visit 1). any member of the study team or sponsor. an immediate family member or household member of the study's personnel. booster vaccination (adolescents) in addition to the above described eligibility criteria, the following criteria must be met: - participant has completed the primary vaccination schedule per protocol (i.e. has received 2 study vaccinations within protocol windows).

1. participant is pregnant or planning to become pregnant within 3 months after study vaccine administration. 2. history of allergy to any component of the vaccine. 3. significant infection (e.g. positive sars-cov-2 rt-pcr) or other acute illness, including fever > 100 °f (> 37.8 °c) 48 hours before vaccination. 4. participant has a known or suspected defect of the immune system 5. participant has a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome. 6. participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. if there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the participant may be enrolled. a history of hematologic malignancy is a permanent exclusion. participants with a history of skin cancer must not be vaccinated at the previous tumour site. 7. history of drug dependency or current use of drug of abuse or alcohol abuse at screening. 8. significant blood loss (> 450 ml) or has donated 1 or more units of blood or plasma within 6 weeks prior to the expected day of randomization (visit 1). 9. history of clinically significant bleeding disorder, or prior history of significant bleeding or bruising following im injections or venepuncture. 10. severe and uncontrolled ongoing autoimmune or inflammatory disease history of guillain-barre syndrome or any other demyelinating condition. 11. any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the volunteer prior/concomitant therapy: 12. receipt of immunoglobulin or another blood product within the 3 months before expected day of randomization (visit 1) in this study or those who expect to receive immunoglobulin or another blood product during this study. 13. receipt of medications and or vaccinations intended to prevent covid-19. 14. receipt of any vaccine (licensed or investigational), other than licensed influenza vaccine, within 28 days prior to the expected day of randomization (visit 1). 15. any member of the study team or sponsor. 16. an immediate family member or household member of the study's personnel. booster vaccination (adolescents) in addition to the above described eligibility criteria, the following criteria must be met: - participant has completed the primary vaccination schedule per protocol (i.e. has received 2 study vaccinations within protocol windows).

1. participant is pregnant or planning to become pregnant within 3 months after study vaccine administration. 2. history of allergy to any component of the vaccine. 3. significant infection (e.g. positive sars-cov-2 rt-pcr) or other acute illness, including fever > 100 °f (> 37.8 °c) 48 hours before vaccination. 4. participant has a known or suspected defect of the immune system 5. participant has a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome. 6. participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. if there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the participant may be enrolled. a history of hematologic malignancy is a permanent exclusion. participants with a history of skin cancer must not be vaccinated at the previous tumour site. 7. history of drug dependency or current use of drug of abuse or alcohol abuse at screening. 8. significant blood loss (> 450 ml) or has donated 1 or more units of blood or plasma within 6 weeks prior to the expected day of randomization (visit 1). 9. history of clinically significant bleeding disorder, or prior history of significant bleeding or bruising following im injections or venepuncture. 10. severe and uncontrolled ongoing autoimmune or inflammatory disease history of guillain-barre syndrome or any other demyelinating condition. 11. any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the volunteer prior/concomitant therapy: 12. receipt of immunoglobulin or another blood product within the 3 months before expected day of randomization (visit 1) in this study or those who expect to receive immunoglobulin or another blood product during this study. 13. receipt of medications and or vaccinations intended to prevent covid-19. 14. receipt of any vaccine (licensed or investigational), other than licensed influenza vaccine, within 28 days prior to the expected day of randomization (visit 1). 15. any member of the study team or sponsor. 16. an immediate family member or household member of the study's personnel. booster vaccination (adolescents) in addition to the above described eligibility criteria, the following criteria must be met: - participant has completed the primary vaccination schedule per protocol (i.e. has received 2 study vaccinations within protocol windows).

1. participant is pregnant or planning to become pregnant within 3 months after study vaccine administration. 2. history of allergy to any component of the vaccine. 3. significant infection (e.g. positive sars-cov-2 rt-pcr) or other acute illness, including fever > 100 °f (> 37.8 °c) 48 hours before vaccination. 4. participant has a known or suspected defect of the immune system 5. participant has a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome. 6. participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. if there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the participant may be enrolled. a history of hematologic malignancy is a permanent exclusion. participants with a history of skin cancer must not be vaccinated at the previous tumour site. 7. history of drug dependency or current use of drug of abuse or alcohol abuse at screening. 8. significant blood loss (> 450 ml) or has donated 1 or more units of blood or plasma within 6 weeks prior to the expected day of randomization (visit 1). 9. history of clinically significant bleeding disorder, or prior history of significant bleeding or bruising following im injections or venepuncture. 10. severe and uncontrolled ongoing autoimmune or inflammatory disease history of guillain-barre syndrome or any other demyelinating condition. 11. any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the volunteer prior/concomitant therapy: 12. receipt of immunoglobulin or another blood product within the 3 months before expected day of randomization (visit 1) in this study or those who expect to receive immunoglobulin or another blood product during this study. 13. receipt of medications and or vaccinations intended to prevent covid-19. 14. receipt of any vaccine (licensed or investigational), other than licensed influenza vaccine, within 28 days prior to the expected day of randomization (visit 1). 15. any member of the study team or sponsor. 16. an immediate family member or household member of the study's personnel.

1. participant is pregnant or planning to become pregnant within 3 months after study vaccine administration. 2. history of allergy to any component of the vaccine. 3. significant infection (e.g. positive sars-cov-2 rt-pcr) or other acute illness, including fever > 100 °f (> 37.8 °c) 48 hours before vaccination. 4. participant has a known or suspected defect of the immune system 5. participant has a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome. 6. participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. if there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the participant may be enrolled. a history of hematologic malignancy is a permanent exclusion. participants with a history of skin cancer must not be vaccinated at the previous tumour site. 7. history of drug dependency or current use of drug of abuse or alcohol abuse at screening. 8. significant blood loss (> 450 ml) or has donated 1 or more units of blood or plasma within 6 weeks prior to the expected day of randomization (visit 1). 9. history of clinically significant bleeding disorder, or prior history of significant bleeding or bruising following im injections or venepuncture. 10. severe and uncontrolled ongoing autoimmune or inflammatory disease history of guillain-barre syndrome or any other demyelinating condition. 11. any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the volunteer prior/concomitant therapy: 12. receipt of immunoglobulin or another blood product within the 3 months before expected day of randomization (visit 1) in this study or those who expect to receive immunoglobulin or another blood product during this study. 13. receipt of medications and or vaccinations intended to prevent covid-19. 14. receipt of any vaccine (licensed or investigational), other than licensed influenza vaccine, within 28 days prior to the expected day of randomization (visit 1). 15. any member of the study team or sponsor. 16. an immediate family member or household member of the study's personnel.